Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
Roswell Park Cancer Institute
Roswell Park Cancer Institute
University of California, Davis
Wake Forest University Health Sciences
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
M.D. Anderson Cancer Center
North Eastern German Society of Gynaecological Oncology
Ohio State University Comprehensive Cancer Center
Mayo Clinic
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Mayo Clinic
Massachusetts General Hospital
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Wake Forest University Health Sciences
Brown University
M.D. Anderson Cancer Center
University Health Network, Toronto
University of Washington
Jonsson Comprehensive Cancer Center
The Netherlands Cancer Institute
The University of Hong Kong
The University of Hong Kong
University of Pittsburgh
Universitaire Ziekenhuizen KU Leuven
University of Chicago
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
Instituto do Cancer do Estado de São Paulo
Roswell Park Cancer Institute
Thomas Jefferson University
Mario Negri Institute for Pharmacological Research
Mayo Clinic
Mercy Medical Center
Roswell Park Cancer Institute
Imperial College London
Beth Israel Deaconess Medical Center
Peking University Cancer Hospital & Institute
Yale University
Jonsson Comprehensive Cancer Center
University College, London
M.D. Anderson Cancer Center
Albert Einstein College of Medicine
Northwestern University
University Health Network, Toronto
University Health Network, Toronto
Guangxi Medical University
University of Miami
Ludwig Institute for Cancer Research
Sun Yat-sen University
Peter MacCallum Cancer Centre, Australia